2nd Quarter Earnings Presentation Materials

Overview of Performance

In the 2nd quarter of this fiscal year, revenue grew substantially year-on-year driven by strong performance in the domestic medical device market and the U.S. water treatment market, as well as demand from Asia's semiconductor and LCD markets. Inventory optimization reduced cost of goods sold ratio, and despite a slight increase in SG&A ratio, operating margin reached a record high since listing. By segment, strength in semiconductor & LCD, medical devices, and surface treatment equipment contributed. Equity-method investment income also supported results, lifting profit at each stage including ordinary income, and interim net income attributable to owners of the parent increased significantly by 47.5% year-on-year.

Outlook and Financial Targets

For the fiscal year ending March 2027, the company expects revenue growth in the second half assuming continued strength in the semiconductor & LCD, medical device, and surface treatment equipment markets, and anticipates improvement in operating margin. The financial targets of the Medium-Term Management Plan 2027 are expected to be largely achieved. Some foreign exchange sensitivity is assumed to have an impact in the second half.